Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levocabastine Hydrochloride

FDA-approved product (suspension/drops, ophthalmic), marketed as Livostin.

Registered studies
5
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Levocabastine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye allergy
  • Nasal congestion

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antiallergic agents, excl. corticosteroids; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levocabastine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levocabastine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

    NCT04002349 · start 2019-07-01

    Registered record
    Registry ID
    NCT04002349
    Conditions
    Determination of the Efficacy of Different Medications for Idiopathic Rhinitis; Impact of Different Medications on Biomarkers of Idiopathic Rhinitis; Safety and Tolerance of Different Medications for Idiopathic Rhinitis
    Interventions
    Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.); Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.); 0.9% natural saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-07-01
    Completion
    2020-03-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDetermination of the Efficacy of Different Medications for Idiopathic Rhinitis; Impact of Different Medications on Biomarkers of Idiopathic Rhinitis; Safety and Tolerance of Different Medications for Idiopathic Rhinitis
    InterventionBudesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.); Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.); 0.9% natural saline
    PhaseNot applicable
    Registry statusUnknown

  • Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

    NCT02498509 · start 2015-05

    Registered record
    Registry ID
    NCT02498509
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    CKD-342; Mometasone furoate; Levocabastine HCL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2016-05
    Enrolment
    459

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionCKD-342; Mometasone furoate; Levocabastine HCL
    PhasePhase 3
    Registry statusCompleted

  • A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

    NCT01962467 · start 2013-10-11

    Registered record
    Registry ID
    NCT01962467
    Conditions
    Rhinitis, Allergic, Perennial and Seasonal
    Interventions
    FF/LEV FDC; FF; LEV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10-11
    Completion
    2014-02-27
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial and Seasonal
    InterventionFF/LEV FDC; FF; LEV
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis

    NCT01949051 · start 2013-10-01

    Registered record
    Registry ID
    NCT01949051
    Conditions
    Rhinitis, Allergic, Perennial and Seasonal
    Interventions
    Levocabastine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2014-02-04
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial and Seasonal
    InterventionLevocabastine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)

    NCT01957202 · start 2013-10

    Registered record
    Registry ID
    NCT01957202
    Conditions
    Rhinitis, Allergic, Perennial and Seasonal
    Interventions
    FF/levocabastine; FF; levocabastine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-02
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial and Seasonal
    InterventionFF/levocabastine; FF; levocabastine; Placebo
    PhasePhase 2
    Registry statusCompleted